This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
James W. Fawcett published the review « The extracellular matrix in plasticity and regeneration after CNS injury and neurodegenerative disease » in 2015, highlighting the key role of the chondroitin sulfate proteoglycans (CSPGs) of the Read more…
Last week, our study director Elodie was in Rennes to participate in NutrEvent! We had a booth there, under NSL Clubster pavilion (Lille Northern France Health and Nutrition clubster). It was a pleasure for her Read more…
Elodie is waiting for you on the first floor at Nutr’event 2019! HCS Pharma stand is n° D6/2, on Clubster NHL pavilion. She will be glad to discuss with you about: our in vitro tests Read more…
Since last year, our PhD student Véronique De Conto has been working on the impact of microenvironment in cerebral in vitro model. On the supervision of our study director Dr. Elodie Vandenhaute and her thesis Read more…
We are very happy to be invited by our partner Molecular Devices at the user meeting of Taipei (Taiwan) and Beijing (China) this month to talk about phenotypic screening and 3D cell culture. We will Read more…
With more than 25 countries represented, NutrEvent is THE place to be for business and innovation in Food, Nutrition and Health. It will take place next week in Rennes congress centre (Couvent des Jacobins), on Read more…
With more than 1100 researchers and exhibiting experts, “Rendez-vous Carnot” offers a complete ecosystem of R&D and innovation support. We will attend at two-day Rendez vous CARNOT (October 16-17 in Paris) to present our innovations on 3D Read more…
Last week we were glad to attend the kick-off meeting of MIMLIVEROnChip, funded by the french National Agency for Research (ANR). It was held in UTC Compiègne, and the project is coordinated by Pr Cecile Read more…
It’s a large part of our work to reveal beauty (and secrets!) of cells in HCS Pharma thanks to different microscopy technologies. In this nice article, authors present the evolution of this field from first Read more…
We are very happy to share with you about HCS and 3D in vitro models thanks to a labroots.com webinar on October 27, 2019! This webinar is made with our partner Molecular Devices and it Read more…
The annual congress of Biology and Health PhD students from Lille (André Verbert day) took place at the Faculty of Medicine Thursday, September 10th. During this day, PhD students, in third year of thesis, had Read more…
Ask for high quality link by putting your email below We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs Read more…
In HCS Pharma, we have already talked about Artificial Intelligence (AI) and the way it is useful in picture analysis. AI can obviously be used for many endeavours, like the shortening of drug discovery timeline Read more…
Last week we were glad to attend TERMIS-EU workshop in Nantes, dealing with 3D bioprinting in cancer research. There we presented 3 posters – that you can find on our website! – about BIOMIMESYS® product Read more…
We are very happy to be a part of the innovation landscape in France and to be supported (very efficiently) by BPI France. This year again we will be present at the big “Bpifrance Inno Read more…
The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.
Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.
This project aims at developing a universal “plug and play” platform, flexible and modular, mimicking the major events occurring in the liver sinusoid: barrier/sieving effect resulting from the specific fenestration of liver sinusoidal endothelial cells, biotransformation and metabolism in the hepatocytes themselves.
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
HCS Pharma – Site de Rennes
Biopole
6 Rue Pierre Joseph Colin
35000 RENNES
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.